369 related articles for article (PubMed ID: 30141176)
1. The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?
Michels MAHM; Volokhina EB; van de Kar NCAJ; van den Heuvel LPWJ
Pediatr Nephrol; 2019 Aug; 34(8):1349-1367. PubMed ID: 30141176
[TBL] [Abstract][Full Text] [Related]
2. Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.
Michels MAHM; van de Kar NCAJ; van den Bos RM; van der Velden TJAM; van Kraaij SAW; Sarlea SA; Gracchi V; Oosterveld MJS; Volokhina EB; van den Heuvel LPWJ
Front Immunol; 2019; 10():1350. PubMed ID: 31263464
[TBL] [Abstract][Full Text] [Related]
3. Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation.
Chen JY; Galwankar NS; Emch HN; Menon SS; Cortes C; Thurman JM; Merrill SA; Brodsky RA; Ferreira VP
Front Immunol; 2020; 11():1460. PubMed ID: 32793201
[TBL] [Abstract][Full Text] [Related]
4. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
[TBL] [Abstract][Full Text] [Related]
5. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
6. Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia.
Ueda Y; Miwa T; Gullipalli D; Sato S; Ito D; Kim H; Palmer M; Song WC
J Am Soc Nephrol; 2018 Jul; 29(7):1928-1937. PubMed ID: 29858280
[No Abstract] [Full Text] [Related]
7. The Role of Properdin in C5 Convertase Activity and C5b-9 Formation in the Complement Alternative Pathway.
Michels MAHM; Maas RJF; van der Velden TJAM; van de Kar NCAJ; van den Heuvel LPWJ; Volokhina EB;
J Immunol; 2021 Nov; 207(10):2465-2472. PubMed ID: 34635587
[TBL] [Abstract][Full Text] [Related]
8. Eculizumab in the treatment of membranoproliferative glomerulonephritis.
Bomback AS
Nephron Clin Pract; 2014; 128(3-4):270-6. PubMed ID: 25402185
[TBL] [Abstract][Full Text] [Related]
9. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
Front Immunol; 2018; 9():612. PubMed ID: 29670616
[TBL] [Abstract][Full Text] [Related]
10. Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement.
Kimura Y; Miwa T; Zhou L; Song WC
Blood; 2008 Jan; 111(2):732-40. PubMed ID: 17916747
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae.
Agarwal S; Ferreira VP; Cortes C; Pangburn MK; Rice PA; Ram S
J Immunol; 2010 Jul; 185(1):507-16. PubMed ID: 20530262
[TBL] [Abstract][Full Text] [Related]
12. C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.
Williams AL; Gullipalli D; Ueda Y; Sato S; Zhou L; Miwa T; Tung KS; Song WC
Kidney Int; 2017 Jun; 91(6):1386-1397. PubMed ID: 28139294
[TBL] [Abstract][Full Text] [Related]
13. Evolving complexity of complement-related diseases: C3 glomerulopathy and atypical haemolytic uremic syndrome.
Cook HT
Curr Opin Nephrol Hypertens; 2018 May; 27(3):165-170. PubMed ID: 29517501
[TBL] [Abstract][Full Text] [Related]
14. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.
Paixão-Cavalcante D; López-Trascasa M; Skattum L; Giclas PC; Goodship TH; de Córdoba SR; Truedsson L; Morgan BP; Harris CL
Kidney Int; 2012 Nov; 82(10):1084-92. PubMed ID: 22854646
[TBL] [Abstract][Full Text] [Related]
15. Properdin and complement activation: a fresh perspective.
Hourcade DE
Curr Drug Targets; 2008 Feb; 9(2):158-64. PubMed ID: 18288967
[TBL] [Abstract][Full Text] [Related]
16. Kidney Diseases Associated With Alternative Complement Pathway Dysregulation and Potential Treatment Options.
Sanghera P; Ghanta M; Ozay F; Ariyamuthu VK; Tanriover B
Am J Med Sci; 2017 Dec; 354(6):533-538. PubMed ID: 29208248
[TBL] [Abstract][Full Text] [Related]
17. Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis.
Lesher AM; Zhou L; Kimura Y; Sato S; Gullipalli D; Herbert AP; Barlow PN; Eberhardt HU; Skerka C; Zipfel PF; Hamano T; Miwa T; Tung KS; Song WC
J Am Soc Nephrol; 2013 Jan; 24(1):53-65. PubMed ID: 23204401
[TBL] [Abstract][Full Text] [Related]
18. Functional Hemolytic Test for Complement Alternative Pathway Convertase Activity.
Michels MAHM; van de Kar NCAJ; Volokhina EB; van den Heuvel BLPWJ
Methods Mol Biol; 2021; 2227():83-96. PubMed ID: 33847933
[TBL] [Abstract][Full Text] [Related]
19. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
Marinozzi MC; Chauvet S; Le Quintrec M; Mignotet M; Petitprez F; Legendre C; Cailliez M; Deschenes G; Fischbach M; Karras A; Nobili F; Pietrement C; Dragon-Durey MA; Fakhouri F; Roumenina LT; Fremeaux-Bacchi V
Kidney Int; 2017 Nov; 92(5):1232-1241. PubMed ID: 28712854
[TBL] [Abstract][Full Text] [Related]
20. Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis.
Aradottir SS; Kristoffersson AC; Roumenina LT; Bjerre A; Kashioulis P; Palsson R; Karpman D
Front Immunol; 2021; 12():690821. PubMed ID: 34177949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
